Derma Sciences Initiates Enrollment in DSC127 Phase III Trial for Healing Diabetic Foot Ulcers

February 6, 2013
Derma Sciences, a medical device and pharmaceutical company focused on advanced wound care, announces that enrollment of patients has commenced in the first of two Phase III clinical trials with the company’s investigational topical drug candidate DSC127.
Yahoo! Medical News